Loading clinical trials...
Loading clinical trials...
Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (SC) Doses Of The Proposed Pegfilgrastim Biosimilar (PF-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers
Conditions
Interventions
PF-06881894
US-approved Neulasta
Locations
4
United States
Seaview A Quotient Clinical Business
Coral Gables, Florida, United States
Quotient Sciences- Jacksonville, LLC
Jacksonville, Florida, United States
Seaview A Quotient Clinical Business
Miami, Florida, United States
Vince & Associates Clinical Research Inc.
Overland Park, Kansas, United States
Start Date
October 27, 2017
Primary Completion Date
July 25, 2018
Completion Date
July 25, 2018
Last Updated
September 5, 2018
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions